Cargando…
Evaluating Potential Impacts of a Preferential Vaccine Recommendation for Adults 65 Years of Age and Older on US Influenza Burden
High-dose, adjuvanted, and recombinant influenza vaccines may offer improved effectiveness among older adults compared with standard-dose, unadjuvanted, inactivated vaccines. However, the Advisory Committee on Immunization Practices (ACIP) only recently recommended preferential use of these “higher-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069750/ https://www.ncbi.nlm.nih.gov/pubmed/36807266 http://dx.doi.org/10.1097/EDE.0000000000001603 |
_version_ | 1785018909747838976 |
---|---|
author | Morris, Sinead E. Grohskopf, Lisa A. Ferdinands, Jill M. Reed, Carrie Biggerstaff, Matthew |
author_facet | Morris, Sinead E. Grohskopf, Lisa A. Ferdinands, Jill M. Reed, Carrie Biggerstaff, Matthew |
author_sort | Morris, Sinead E. |
collection | PubMed |
description | High-dose, adjuvanted, and recombinant influenza vaccines may offer improved effectiveness among older adults compared with standard-dose, unadjuvanted, inactivated vaccines. However, the Advisory Committee on Immunization Practices (ACIP) only recently recommended preferential use of these “higher-dose or adjuvanted” vaccines. One concern was that individuals might delay or decline vaccination if a preferred vaccine is not readily available. METHODS: We mathematically model how a recommendation for preferential use of higher-dose or adjuvanted vaccines in adults ≥65 years might impact influenza burden in the United States during exemplar “high-” and “low-”severity seasons. We assume higher-dose or adjuvanted vaccines are more effective than standard vaccines and that such a recommendation would increase uptake of the former but could cause (i) delays in administration of additional higher-dose or adjuvanted vaccines relative to standard vaccines and/or (ii) reductions in overall coverage if individuals only offered standard vaccines forego vaccination. RESULTS: In a best-case scenario, assuming no delay or coverage reduction, a new recommendation could decrease hospitalizations and deaths in adults ≥65 years by 0%–4% compared with current uptake. However, intermediate and worst-case scenarios, with assumed delays of 3 or 6 weeks and/or 10% or 20% reductions in coverage, included projections in which hospitalizations and deaths increased by over 7%. CONCLUSIONS: We estimate that increased use of higher-dose or adjuvanted vaccines could decrease influenza burden in adults ≥65 in the United States provided there is timely and adequate access to these vaccines, and that standard vaccines are administered when they are unavailable. |
format | Online Article Text |
id | pubmed-10069750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-100697502023-04-04 Evaluating Potential Impacts of a Preferential Vaccine Recommendation for Adults 65 Years of Age and Older on US Influenza Burden Morris, Sinead E. Grohskopf, Lisa A. Ferdinands, Jill M. Reed, Carrie Biggerstaff, Matthew Epidemiology Infectious Diseases High-dose, adjuvanted, and recombinant influenza vaccines may offer improved effectiveness among older adults compared with standard-dose, unadjuvanted, inactivated vaccines. However, the Advisory Committee on Immunization Practices (ACIP) only recently recommended preferential use of these “higher-dose or adjuvanted” vaccines. One concern was that individuals might delay or decline vaccination if a preferred vaccine is not readily available. METHODS: We mathematically model how a recommendation for preferential use of higher-dose or adjuvanted vaccines in adults ≥65 years might impact influenza burden in the United States during exemplar “high-” and “low-”severity seasons. We assume higher-dose or adjuvanted vaccines are more effective than standard vaccines and that such a recommendation would increase uptake of the former but could cause (i) delays in administration of additional higher-dose or adjuvanted vaccines relative to standard vaccines and/or (ii) reductions in overall coverage if individuals only offered standard vaccines forego vaccination. RESULTS: In a best-case scenario, assuming no delay or coverage reduction, a new recommendation could decrease hospitalizations and deaths in adults ≥65 years by 0%–4% compared with current uptake. However, intermediate and worst-case scenarios, with assumed delays of 3 or 6 weeks and/or 10% or 20% reductions in coverage, included projections in which hospitalizations and deaths increased by over 7%. CONCLUSIONS: We estimate that increased use of higher-dose or adjuvanted vaccines could decrease influenza burden in adults ≥65 in the United States provided there is timely and adequate access to these vaccines, and that standard vaccines are administered when they are unavailable. Lippincott Williams & Wilkins 2023-02-20 2023-05 /pmc/articles/PMC10069750/ /pubmed/36807266 http://dx.doi.org/10.1097/EDE.0000000000001603 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Infectious Diseases Morris, Sinead E. Grohskopf, Lisa A. Ferdinands, Jill M. Reed, Carrie Biggerstaff, Matthew Evaluating Potential Impacts of a Preferential Vaccine Recommendation for Adults 65 Years of Age and Older on US Influenza Burden |
title | Evaluating Potential Impacts of a Preferential Vaccine Recommendation for Adults 65 Years of Age and Older on US Influenza Burden |
title_full | Evaluating Potential Impacts of a Preferential Vaccine Recommendation for Adults 65 Years of Age and Older on US Influenza Burden |
title_fullStr | Evaluating Potential Impacts of a Preferential Vaccine Recommendation for Adults 65 Years of Age and Older on US Influenza Burden |
title_full_unstemmed | Evaluating Potential Impacts of a Preferential Vaccine Recommendation for Adults 65 Years of Age and Older on US Influenza Burden |
title_short | Evaluating Potential Impacts of a Preferential Vaccine Recommendation for Adults 65 Years of Age and Older on US Influenza Burden |
title_sort | evaluating potential impacts of a preferential vaccine recommendation for adults 65 years of age and older on us influenza burden |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069750/ https://www.ncbi.nlm.nih.gov/pubmed/36807266 http://dx.doi.org/10.1097/EDE.0000000000001603 |
work_keys_str_mv | AT morrissineade evaluatingpotentialimpactsofapreferentialvaccinerecommendationforadults65yearsofageandolderonusinfluenzaburden AT grohskopflisaa evaluatingpotentialimpactsofapreferentialvaccinerecommendationforadults65yearsofageandolderonusinfluenzaburden AT ferdinandsjillm evaluatingpotentialimpactsofapreferentialvaccinerecommendationforadults65yearsofageandolderonusinfluenzaburden AT reedcarrie evaluatingpotentialimpactsofapreferentialvaccinerecommendationforadults65yearsofageandolderonusinfluenzaburden AT biggerstaffmatthew evaluatingpotentialimpactsofapreferentialvaccinerecommendationforadults65yearsofageandolderonusinfluenzaburden |